- Home
- AVTX vs VTGN Comparison
AVTX vs VTGN Comparison
Compare AVTX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- VTGN
- Stock Information
- Founded
- AVTX 2011
- VTGN 1998
- Country
- AVTX United States
- VTGN United States
- Employees
- AVTX N/A
- VTGN N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- VTGN Health Care
- Exchange
- AVTX Nasdaq
- VTGN Nasdaq
- Market Cap
- AVTX 57.4M
- VTGN 59.8M
- IPO Year
- AVTX 2015
- VTGN N/A
- Fundamental
- Price
- AVTX $4.89
- VTGN $2.38
- Analyst Decision
- AVTX Strong Buy
- VTGN
- Analyst Count
- AVTX 7
- VTGN 0
- Target Price
- AVTX $31.00
- VTGN N/A
- AVG Volume (30 Days)
- AVTX 82.2K
- VTGN 306.2K
- Earning Date
- AVTX 08-11-2025
- VTGN 08-12-2025
- Dividend Yield
- AVTX N/A
- VTGN N/A
- EPS Growth
- AVTX N/A
- VTGN N/A
- EPS
- AVTX N/A
- VTGN N/A
- Revenue
- AVTX $441,000.00
- VTGN $486,000.00
- Revenue This Year
- AVTX N/A
- VTGN N/A
- Revenue Next Year
- AVTX N/A
- VTGN $943.32
- P/E Ratio
- AVTX N/A
- VTGN N/A
- Revenue Growth
- AVTX N/A
- VTGN N/A
- 52 Week Low
- AVTX $3.39
- VTGN $1.90
- 52 Week High
- AVTX $16.00
- VTGN $4.21
- Technical
- Relative Strength Index (RSI)
- AVTX 54.89
- VTGN 55.71
- Support Level
- AVTX $4.63
- VTGN $1.99
- Resistance Level
- AVTX $5.02
- VTGN $2.63
- Average True Range (ATR)
- AVTX 0.27
- VTGN 0.15
- MACD
- AVTX 0.00
- VTGN 0.05
- Stochastic Oscillator
- AVTX 72.73
- VTGN 60.87
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.